Evolent Health (EVH) Projected to Post Quarterly Earnings on Thursday

Evolent Health (NYSE:EVH - Get Free Report) is projected to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Evolent Health to post earnings of $0.08 per share and revenue of $460.15 million for the quarter. Evolent Health has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The business had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Trading Down 1.2 %

EVH stock traded down $0.12 during midday trading on Tuesday, reaching $10.44. 188,874 shares of the company traded hands, compared to its average volume of 2,362,696. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -12.67 and a beta of 1.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The business has a 50 day moving average of $9.50 and a 200-day moving average of $11.83. Evolent Health has a 52-week low of $8.35 and a 52-week high of $33.63.

Insider Transactions at Evolent Health

In other news, CEO Seth Blackley acquired 55,225 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the acquisition, the chief executive officer now directly owns 762,217 shares in the company, valued at approximately $6,867,575.17. This represents a 7.81 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Diane Holder purchased 2,735 shares of the stock in a transaction on Thursday, March 6th. The shares were purchased at an average cost of $9.33 per share, with a total value of $25,517.55. Following the transaction, the director now owns 70,584 shares of the company's stock, valued at $658,548.72. This trade represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,000 shares of company stock worth $666,315 in the last three months. Company insiders own 1.60% of the company's stock.

Institutional Investors Weigh In On Evolent Health

A hedge fund recently bought a new stake in Evolent Health stock. Brighton Jones LLC purchased a new stake in Evolent Health, Inc. (NYSE:EVH - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 349,109 shares of the technology company's stock, valued at approximately $3,927,000. Brighton Jones LLC owned approximately 0.30% of Evolent Health at the end of the most recent quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on EVH shares. UBS Group decreased their price objective on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, January 16th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price (down from $17.00) on shares of Evolent Health in a research report on Friday, February 21st. Citigroup dropped their price target on Evolent Health from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Canaccord Genuity Group lowered their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.